Trial Profile
An Open-label, Fixed Sequence Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeated Dose of Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Bupropion (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 05 Dec 2018 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 15 Jul 2016 Status changed from not yet recruiting to completed.
- 18 Mar 2016 Planned initiation date changed from 1 Mar 2016 to 1 May 2016 as per ClinicalTrials.gov record.